Amedisys (AMED) Tops Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Amedisys Reports Second Quarter 2017 Financial Results
July 26, 2017 5:00 PM EDTBATON ROUGE, La., July 26, 2017 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2017.
Three Month Periods Ended June 30, 2017 and 2016
Net service revenue increased $18.1Â million to $378.8Â million compared to $360.7Â million in 2016.Net income attributable to Amedisys, Inc. of $4.5Â million compared to $10.7Â million in 2016.Net income attributable to Amedisys, Inc. per diluted share of $0.13 compared to $0.32 in 2016.Adjusted Quarterly Results*
Adjusted EBITDA of $36.1Â million compared to $29.8Â million in 2016.Adjusted net service revenue of $378.8Â million compared to... More